A detailed history of Samsara Bio Capital, LLC transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Samsara Bio Capital, LLC holds 689,709 shares of VIRX stock, worth $151,735. This represents 0.19% of its overall portfolio holdings.

Number of Shares
689,709
Previous 689,709 -0.0%
Holding current value
$151,735
Previous $703,000 47.08%
% of portfolio
0.19%
Previous 0.22%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$1.38 - $2.29 $951,798 - $1.58 Million
689,709 New
689,709 $1.1 Million
Q2 2022

Aug 15, 2022

SELL
$1.87 - $5.0 $39,887 - $106,650
-21,330 Reduced 3.0%
689,709 $2.68 Million
Q2 2021

Aug 17, 2021

SELL
$7.55 - $12.95 $910,424 - $1.56 Million
-120,586 Reduced 14.5%
711,039 $8.06 Million
Q1 2021

May 18, 2021

BUY
$7.58 - $18.67 $6.3 Million - $15.5 Million
831,625 New
831,625 $7.69 Million

Others Institutions Holding VIRX

About Viracta Therapeutics, Inc.


  • Ticker VIRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,558,200
  • Market Cap $8.26M
  • Description
  • Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...
More about VIRX
Track This Portfolio

Track Samsara Bio Capital, LLC Portfolio

Follow Samsara Bio Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Samsara Bio Capital, LLC with notifications on news.